Noteworthily, once trastuzumab binds to the HER-2/neu receptor on target cells, it can also prevent homologous or heterodimerization of the receptor (HER2/HER3) and inhibit the activation of mitogen activated protein-kinase(MAPK) and PI3K/AKT signal pathway, finally preventing the growth of tumor cells. Here, ERBB2 is linked to neoplasm.